What's Happening?
4DMedical Limited has received CE Mark certification for its CT:VQ imaging technology, allowing for its commercial launch across the European Union. This technology provides non-contrast, ventilation-perfusion imaging, offering quantitative lung insights
from routine CT scans without the need for radiotracers. The company has also secured AU$83 million in private placement funding to support its growth initiatives, including the European expansion. The CE Mark certification is a significant milestone for 4DMedical, enabling it to tap into one of the world's largest respiratory imaging markets.
Why It's Important?
The CE Mark certification for CT:VQ represents a major advancement for 4DMedical, as it opens up access to the European market, which has a well-established healthcare infrastructure and a high demand for advanced imaging solutions. This expansion is expected to enhance the company's market presence and drive revenue growth. The technology addresses a critical need in respiratory imaging by providing functional insights without the limitations of traditional nuclear VQ scanning. This could lead to improved diagnostic capabilities and patient outcomes, benefiting healthcare providers and patients across Europe.
